STOCKHOLM, Nov. 12, 2019 /PRNewswire/ -- SciBase a leading
developer of electrical impedance spectroscopy systems in
dermatology, announced today that The Kimberly and Eric J.
Waldman Department of Dermatology at Mount Sinai has become the
first Health System in the United
States to order multiple Nevisense systems in their new
melanoma center. The Mount Sinai health system encompasses
eight hospitals, a leading medical school, and a vast network of
ambulatory practices throughout the greater New York region making it the largest system
in the region.
"We are excited about integrating the Nevisense system in our
new melanoma center and offer our patients advanced technology to
optimize the clinical management of their atypical lesions.
It further supports our commitment to adopt next-generation
solutions to improve patient care and outcomes while offering our
providers state-of-the-art tools to do so" said Dr. Mark Lebwohl, Waldman Professor and Chairman of
the Kimberly and Eric J. Waldman Department of Dermatology at the
Icahn School of Medicine at Mount Sinai.
"The inclusion of EIS technology will allow us to provide
patients with important risk information. This will help
differentiate the Mount Sinai melanoma center while also providing
our patients with best in class care", said Dr. Jonathan Ungar, assistant professor of
dermatology and medical education at Mount Sinai.
"We are observing a demand for augmented intelligence within
dermatology in the US and SciBase is proud to install multiple
Nevisense systems within one of the largest health systems in the
US and the largest in the New York
region." said Simon Grant, Chief
Executive Officer of Scibase. "This multi system order marks a key
milestone in SciBase' US market penetration strategy and we are
excited about the growing adoption of the Nevisense method."
For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46-72-887-43-99
Email: simon.grant@scibase.com
Certified Advisor:
Avanza
Tel: +46-409-421-20
Email: corp@avanza.se
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company and a global
leader in breakthrough point-of-care technology for the evaluation
of skin disorders such as skin cancer and atopic dermatitis.
Their flagship product Nevisense assists physicians in the
detection of melanoma at its earliest, most curable stage.
Melanoma is the deadliest form of skin cancer and has an
almost 100% cure rate if caught early. Further development has led
to Nevisense also being used as a tool to assess the skin barrier
and inflammation in research. SciBase was founded by Stig Ollmar,
Associate Professor at The Karolinska
Institute in Stockholm,
Sweden. Nevisense is based on substantial research and has
achieved excellent results in the largest clinical study ever
conducted on the detection of malignant melanoma. Nevisense is CE
marked in Europe, has TGA approval
in Australia and is FDA Approved
in the United States. Nevisense is
based on a method called Electrical Impedance Spectroscopy (EIS),
which uses the varying electrical properties of human tissue to
categorize cellular structures and thereby detect malignancies and
abnormalities. SciBase is listed on First North Growth Market
("SCIB"). Further information is available at www.scibase.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/scibase/r/scibase-announces-order-of-nevisense-from-mount-sinai-hospital-s-new-melanoma-clinic,c2959921
The following files are available for download:
https://mb.cision.com/Main/12371/2959921/1140104.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/scibase-announces-order-of-nevisense-from-mount-sinai-hospitals-new-melanoma-clinic-300956460.html
SOURCE SciBase